Clinical trials - Press Releases

Date	Title	Company
30-Mar-2023	Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need	Galimedix Therapeutics
30-Mar-2023	NRG Therapeutics Announces International Scientific Advisory Board	NRG Therapeutics
30-Mar-2023	Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress	Molecure S.A.
29-Mar-2023	NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137	NETRIS Pharma
28-Mar-2023	Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients	Evaxion
28-Mar-2023	HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression	HMNC Brain Health
28-Mar-2023	Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer	Novartis
28-Mar-2023	Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)	Tiziana Life Sciences
28-Mar-2023	Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001	Thermosome
23-Mar-2023	Citeline Finalist CluePoints Show Advanced AI Capabilities	CluePoints
23-Mar-2023	Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions	Vaccitech
22-Mar-2023	Greenphire Launches Patient-Powered Research Registry Allowing Foundations to Better Engage and Support Patients	Greenphire
22-Mar-2023	ABPI response to MHRA clinical trials framework	ABPI
22-Mar-2023	Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions	Vaccitech
22-Mar-2023	iO:M8 receives CE-IVD certification	PreciPoint GmbH
21-Mar-2023	MHRA to streamline clinical trial approvals in biggest overhaul of trial regulation in 20 years	MHRA
17-Mar-2023	Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer	Astellas Pharma Ltd
17-Mar-2023	TrakCel and Lonza complete integration milestone to combine cell and gene therapy manufacturing and orchestration solutions	TrakCel
16-Mar-2023	OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website	OKYO Pharma
16-Mar-2023	Clinion Launches Revolutionary AI-Powered Medical Coding Solution for Clinical Trials	clinion